The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Aldose reductase inhibitors: therapeutic implications for diabetic complications
Abstract
The 'late complications' of diabetes mellitus, i.e., nephropathy, neuropathy and retinopathy are firmly rooted in inadequate control of blood glucose: hyperglycaemia. Hyperglycaemia causes elevated cytosolic glucose and/or rates of glucose metabolism, i.e., 'hyperglysolia,' within cells of vulnerable tissues. Although the molecular basis for the pathogenic effects of hyperglysolia remains to be proven, substantial evidence points to a key role for increased glucose metabolism through a cytosolic enzyme, aldose reductase (AR). Recent human genetic and biochemical data link polymorphisms of the AR gene (technically called the AR2 gene) and elevated tissue levels of AR with strongly altered risks for diabetic complications. Despite several genetic reports failing to confirm such an association, there are now ten concordant reports from five continents that certain polymorphisms of the AR gene are associated with an ~ 3- to 20-fold higher risk for diabetic complications. Moreover, in US and European diabetic study populations the principle allele of the AR gene associated with elevated disease risk, the Z-2 allele, correlates with an ~ 2- to 3-fold increase in AR expression. These results, together with recent clinical, experimental and pharmacological data, provide powerful new support for the rationale for research and development of aldose reductase inhibitors (ARIs) targeted at slowing the progression of diabetic complications. Although past clinical trials of ARIs have been disappointing, this has stemmed from overly optimistic expectations, inadequate trial designs and lack of pharmacological robustness and/or acceptable systemic toleration of the agents tested. However, a more realistic and encouraging perspective for therapeutic expectations for ARIs has arisen from recent data revealing that the seemingly modest short-term effects of intensified glycaemic control and of pancreatic transplantation are followed by substantial long-term benefits on diabetic complications. In addition, robust inhibition of AR in human nerve has recently yielded dose-dependent efficacy on nerve structure and function. Thus, the quest for well-tolerated, potent ARIs continues to be a worthy and more urgent objective than ever before.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of oxidative stress in diabetic complications: a new perspective on an old paradigm.
Baynes, J. W., & Thorpe, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.1 · Cited by 2,441
Metabolic and Vascular Factors in the Pathogenesis of Diabetic Neuropathy
Cameron, N. E., & Cotter, M. A. (1997) · Diabetes · doi:10.2337/diab.46.2.s31 · Cited by 312
Hamada, Y., Araki, N., Koh, N., Nakamura, J., Horiuchi, S., & Hotta, N. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1695 · Cited by 169
Digby, J. E., Montague, C. T., Sewter, C. P., Sanders, L., Wilkison, W. O., O'Rahilly, S., & Prins, J. B. (1998) · Diabetes · doi:10.2337/diab.47.1.138 · Cited by 134
Kendall, D. M., Rooney, D. P., Smets, Y. F. C., Salazar Bolding, L., & Robertson, R. P. (1997) · Diabetes · doi:10.2337/diab.46.2.249 · Cited by 134
Cited by
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Lee, R., Wong, T. Y., & Sabanayagam, C. (2015) · Eye and Vision · doi:10.1186/s40662-015-0026-2 · Cited by 1,569
Oxidative Stress in the Pathogenesis of Diabetic Neuropathy
Vincent, A. M., Russell, J. W., Low, P., & Feldman, E. L. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0019 · Cited by 982
Aldose Reductase, Oxidative Stress, and Diabetic Mellitus
Tang, W. H., Martin, K. A., & Hwa, J. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00087 · Cited by 458
Hotta, N., Akanuma, Y., Kawamori, R., Matsuoka, K., Oka, Y., Shichiri, M., Toyota, T., Nakashima, M., Yoshimura, I., Sakamoto, N., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2370 · Cited by 366
Polyol pathway and diabetic peripheral neuropathy
Oates, P. J. (2002) · International Review of Neurobiology · doi:10.1016/s0074-7742(02)50082-9 · Cited by 322
Self-citation
Metadata
- Authors
- Oates, P. J., & Mylari, B. L.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 1999-12
- Volume
- 8
- Issue
- 12
- Pages
- 2095-2119
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2155295568
- Cited by
- 197
- References
- 5
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aldose reductase inhibitors: therapeutic implications for diabetic complications. https://app.cochat.ai/papers/10.1517/13543784.8.12.2095
- The paper
- Oates, P. J., & Mylari, B. L. (1999). Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.8.12.2095
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.